Pieris Pharmaceuticals, Inc.

NASDAQ
PIRS
paper.types.company
Rentabilité sur six mois: -19.19%
Rendement en dividendes: 0%
Secteur: Healthcare

13.6 $

0 $ 0%
6.53 $
18.47 $

paper.min_max_per_year

Calendrier des promotions Pieris Pharmaceuticals, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis.

plus de détails
The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2015-04-13
ISIN
US7207951036
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0.3316 10
P/BV 0.5305 10
P/E 0 0
Efficacité
Nom Signification Grade
ROA -63.45 0
ROE -91.72 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.9315 10
Debt/Ratio 0.3387 10
Debt/Equity 0.4455 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % -7.54 0
Rentabilité Ebitda, % -12.79 0
Rentabilité EPS, % 4546.31 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 13.6 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 13.6 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.30d 13.6 $ 13.6 $ 13.6 $ 0 % 0 % 0 %
common.calendar.number_days.90d 13.6 $ 13.6 $ 13.6 $ 0 % 0 % 0 %
common.calendar.number_days.180d 16.83 $ 13.6 $ 16.6 $ -19.19 % 0 % 0 %
common.calendar.number_days.1y 9.6 $ 6.53 $ 18.47 $ 41.67 % 0 % 0 %
common.calendar.number_days.3y 1.7 $ 0.14 $ 18.47 $ 700 % 0 % 0 %
common.calendar.number_days.5y 2.34 $ 0.14 $ 18.47 $ 481.2 % 0 % 0 %
common.calendar.number_days.10y 0 $ 0.14 $ 18.47 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 13.6 $ 13.6 $ 13.6 $ 0 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Stephen S. Yoder J.D. CEO, President & Director 744.13k 1976 (49 années)
Mr. Thomas Bures Senior VP, CFO & Treasurer 487.5k 1975 (50 années)
Maria Kelman Executive Director of Investor Relations N/A
Dr. Shane Olwill Ph.D. Senior VP & Chief Development Officer 463.91k 1976 (49 années)
Mr. Prompong Chaikul Chief Supply Chain Officer N/A 1987 (38 années)

Informations sur l'entreprise

Adresse: United States, Boston. MA, 225 Franklin Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.pieris.com